Clinical research
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 9, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 8, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 7, 2020.
“Today’s announcement marks a significant milestone towards fulfilling our promise to patients globally with TNBC of providing a new treatment option that can meaningfully improve their lives,” said Behzad Aghazadeh, executive chairman of Immunomedics.
The research was presented at the Revolutionizing Atopic Dermatitis Virtual Symposium.
Menlo Therapeutics released topline results from two Phase III trials of once daily oral serlopitant for pruritus (itching) associated with prurigo nodularis. Neither trial met their primary endpoint.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 6, 2020.
One of the promising experimental drugs being tested to treat COVID-19, the disease caused by the novel coronavirus SARS-Cov2-, is Gilead Sciences’ remdesivir.
During a presentation at the AAT-AD/PD 2020 conference, Axon said AADvac1 showed a disease-modifying effect on Alzheimer’s disease.
This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
PRESS RELEASES